explore -WSS

explore

author：leisure time 2025-09-28 18:47:34 - browse：62683

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： White House Covid adviser calls on docs to combat misinformation

hotspot

WSS

Here’s what’s in the FDA plan to include pregnant women in clinical trials

FDA panel to weigh safety of artificial wombs for preterm births

Congress must protect the remaining independent doctors

FDA panel to weigh safety of artificial wombs for preterm births

Ebola vaccine can save some who are already sick, per new study

Grad students accuse University of California of wage theft

entertainment

explore

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The unintended consequences of overturning Roe v. Wade

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bernie Sanders gets little from pharma CEOs on drug prices

State Dept. review finds Biden bears some blame for Afghanistan failures

David Liu startup to focus on CRISPR delivery

In age of alternative facts, a scholarly course on calling out crap

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

hotspot

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

People with substance use disorder deserve online privacy

Abbott's new heart device gets FDA advisory panel nod

The struggle to figure out which patients 'deserve' Wegovy

Midwives could help bridge maternal health disparities in the U.S.

Why the quest to eradicate polio has stumbled

entertainment

entertainment

hotspot

entertainment